Cell lines xenograft-derived breast cancer cells

YC-1,3-(5 -hydroxymethyl-2 -furyl)-l-benzylindazole, a soluble guanylyl cyclase stimulator, has been shown in several xenograft cancer models to inhibit HIF-la protein expression and to have anti-angiogenic activity [212]. In addition, in an animal model of metastasis, YC-1 treatment dramatically reduced cell migration and metastatic burden [213]. Likewise, YC-1 treatment has been shown to decrease bone metastases derived from MDA-MD-231 breast cancer cells that were introduced into animals by intracardiac injection [214]. YC-1 was recently reported in a human lung cancer cell line to also reduce cell proliferation to block activation of matrix metalloproteinases (MMP-2 and MMP-9) and to reduce cyclin D1 expression [215]. However, to date no clinical trials using YC-1 have been initiated. 

---